SEARCH

SEARCH BY CITATION

References

  • Ahmed HH, Hamza AH (2009). Potential role of arginine, glutamine and taurine in ameliorating osteoporotic markers in ovariectomized rats. Report and Opinion 1: 2435.
  • Alatalo SL, Penq Z, Janckila AJ, Kaija H, Vihko P, Vaananen HK et al. (2003). A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res 18: 134139.
  • Alexander SPH et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Overview. Br J Pharmacol 170: 14491867.
  • Antun FT, Burnett GB, Cooper AJ, Daly RJ, Smythies JR, Zealley AK (1971). The effects of methionine on schizophrenia. J Psychatr Res 8: 6371.
  • Beral V, Million Women Study Collaborators (2003). Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 362: 419427.
  • Brandy ML (1993). New treatment strategies: ipriflavone, strontium, vitamin D metabolites and analogs. Am J Med 95: 69S74S.
  • Bridgeman MB, Pathak R (2011). Denosumab for the reduction of bone loss in post menopausal osteoporosis: a review. Clin Ther 33: 15471549.
  • Brueckmann M, Hoffmann U, Dvortsak E, Lang S, Kaden JJ, Borggrefe M et al. (2004). Drotrecogin alfa (activated) NF-KB activation and MIP-α release from isolated mononuclear cells of patients with severe sepsis. Inflam Res 53: 528533.
  • Choi SJ, Cruz JC, Craig FC, Chung H, Devlin RD, Roodman D et al. (2000). Macrophage inflammatory protein-1α is a potential osteoclast stimulatory factor in multiple myeloma. Blood 96: 671675.
  • Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J et al. (2001). Antisense inhibition of macrophage inflammatory protein-1α blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108: 18331841.
  • Cordomi A, Tamayo J, Gigoux V, Fourmy D (2013). Sulphur containing amino acids in 7-TMRs: molecular gears for pharmacology and function. Trends in Pharmacol 34: 320331.
  • D'Amelio P, Grimaldi A, Di Bella S, Tamone C, Brianza SZM, Ravazzoli MGA et al. (2008). Risedronate reduces osteoclast precursors and cytokine production in postmenopausal osteoporotic women. J Bone Mineral Res 23: 373379.
  • Delrieu F, Ferrand B, Amor B (1988). Preliminary study of L-methionine in the treatment of rheumatoid polyarthritis. Rev Rhum Mal Osteoartic 55: 995997.
  • Ernesto C (2000). Novel treatment for osteoporosis. J Clin Invest 106: 177179.
  • Feng X, McDonald JM (2011). Disorders of bone remodeling. Annu Rev Pathol 6: 121145.
  • Fine DH, Markowitz K, Furgang D, Fairlie K, Ferrandiz J, Nasri C (2009). Macrophage inflammatory protein-1α: a salivary biomarker of bone loss in a longitudinal cohort study of children at risk for aggressive periodontal disease? J Periodontol 80: 106113.
  • Fini M, Torricelli P, Giavaresi G, Carpi A, Nicolini A, Giardino R (2001). Effect of L-lysine and L-arginine on primary osteoblast cultures from normal and osteopenic rats. Biomed Pharmacother 55: 213220.
  • Fink HA, Ewing SK, Ensrud KE, Barrett-Connor E, Taylor BC, Cauley JA et al. (2006). Association of testosterone and estradiol deficiency with osteoporosis and rapid bone loss in older men. J Clin Endocrinol Metab 91: 39083915.
  • Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ et al. (1999). Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 96: 133138.
  • Fuller K, Owens JM, Jagger CJ, Wilson A, Moss R, Chambers TJ (1993). Macrophage colony-stimulating factor stimulates survival and chemotactic behavior in isolated osteoclasts. J Exp Med 178: 17331740.
  • Gao Y, Grassi F, Ryan MR, Terauchi M, Page K, Yang X et al. (2007). IFN-γ stimulates osteoclast formation and bone loss in vivo via antigen-driven T cell activation. J Clin Invest 117: 122132.
  • Handa R (2004). Management of osteoporosis, the Indian perspective. Clin Calcium 14: 100105.
  • Iotsova V, Caamaño J, Loy J, Yang Y, Lewin A, Bravo R (1997). Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 11: 12851289.
  • Itoh K, Udagawa N, Kobayashi K, Suda K, Li X, Takami M et al. (2003). Lipopolysaccharide promotes the survival of osteoclasts via toll like receptor-4, but cytokine production in response to lipopolysaccharide is different from that of macrophages. J Immunol 170: 36883695.
  • Jakob F (2005). Primary and secondary osteoporosis. The important role of internal medicine in its differential diagnosis. Internist (Berlin) 46: S24S30.
  • Jiang MY, Cai DP (2011). Oral arginine improves linear growth of long bones and neuroendocrine mechanism. Neurosci Bull 27: 156162.
  • Kerstetter JE, O'Brien K, Insogna KL (2003). Dietary protein, calcium metabolism and skeletal homeostasis revisited. Am J Clin Nutr 78: 584S5592.
  • Kimball SR, Jefferson LS (2004). Molecular mechanisms through which amino acids mediate signaling through the mammalian target of rapamycin. Curr Opin Clin Nutr Metab Care 7: 3944.
  • Kimball SR, Jefferson LS (2006). New functions for amino acids: effects on gene transcription and translation. Am J Clin Nutr 83: 500S507S.
  • Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 15771579.
  • Lacey DL, Timms E, Tan HL, Kelley MJ, Dunstan CR, Burgess T et al. (1998). Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165176.
  • McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 15731576.
  • Meininger V, Flamier A, Phan T, Ferris O, Uzan A, Lefur G (1982). L-methionine treatment of Parkinson's disease: preliminary results. Rev Neurol (Paris) 138: 297303.
  • Nancy EL (2006). Epidemiology, etiology and diagnosis of osteoporosis. Am J Obstet Gynecol 194: S311.
  • Novack DV (2011). Role of NF-KB in the skeleton. Cell Res 21: 169182.
  • Oh S, Sul O, Kim Y, Kim H, Yu R, Suh J et al. (2010). Saturated fatty acids enhance osteoclast survival. J Lipid Res 51: 892899.
  • Okamatsu Y, Kim D, Battaglino R, Sasaki H, Spate U, Stashenko P (2004). MIP-1γ, promotes receptor activator of NF-κB ligand-induced osteoclast formation and survival. J Immunol 173: 20842090.
  • Pernow Y, Thorén M, Sääf M, Fernholm R, Anderstam B, Hauge EM et al. (2010). Associations between amino acids and bone mineral density in men with idiopathic osteoporosis. Bone 47: 959965.
  • Riggs BL, Khosla S, Melton LJ (2002). 3rd Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 23: 279302.
  • Ritchlin C (2009). The quest for a biomarker of circulating osteoclast precursors. Arthritic Res Ther 11: 113114.
  • Roato I, Grano M, Brunetti G, Colucci S, Mussa A, Bertetto O et al. (2005). Mechanisms of spontaneous osteoclastogenesis in cancer with bone involvement. FASEB J 19: 228230.
  • Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanic ML (2002). Writing group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progesterone in healthy post menopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288: 321333.
  • Rowan A (2006). Neurogenetics: undoing epigenetics. Nat Rev Neurosci 7: 37.
  • Sarvari M, Hrabovszky E, Kallo I, Solymosi N, Liko I, Berchtold N et al. (2012). Menopause leads to elevated expression of macrophage associated genes in the aging frontal cortex: rat and human studies identify strikingly similar changes. J Neuroinflammation 9: 264277.
  • Sato N, Takahashi N, Suda K, Nakamura M, Yamaki M, Ninomiya T et al. (2004). MyD88 but not TRIF is essential for osteoclastogenesis induced by lipopolysaccharide, diacyl lipopeptide and IL-1α. J Exp Med 200: 601611.
  • Seeman E (2003). The structural and biomechanical basis of the gain and loss of bone strength in women and men. Endocrinol Metab Clin North Am 32: 2538.
  • Shi H, Kokoeva MV, Inouye K, Tzameli I, Yin H, Flier JS (2006). TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116: 30153025.
  • Ursini F, Pipicelli G (2009). Nutritional supplementation for osteoarthritis: alternative and complementary therapies. Altern Complement Ther 15: 173177.
  • Wang M, Yao Y, Kuang D, Hampson DR (2006). Activation of family of G-protein coupled receptors by the tripeptide glutathione. J Biol Chem 281: 88648870.
  • WHO Study group (1994). Assessment of fracture risk and its applications to screening for post menopausal osteoporosis. World Health Organ Tech Rep Ser 843: 1129.
  • Wright K (1991). Slowing down the sands of time gerontological research, noting growth hormone, exercise, food restriction, osteoporosis and osteoarthritis. Discover 12: 8485.
  • Yamada A, Takami M, Kawawa T, Yasuhara R, Zhao B, Michizuki A et al. (2007). Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology 120: 573579.
  • Yasui T, Hirose J, Abutatani H, Tanaka S (2011). Epigenetic regulation of osteoclast differentiation. Ann NY Acad Sci 1240: 713.
  • Yoshida H, Hayashi S, Kunisada T, Ogawa M, Nishikawa S, Okamura H et al. (1990). The murine mutation of osteopetrosis is in the coding region of the macrophage colony stimulating factor gene. Nature 345: 442444.